NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax's $3.2 Million Public Offering and Company Overview
TL;DR
GeoVax Labs raised $3.2 million through a public offering, providing capital to advance its cancer and infectious disease therapies ahead of competitors.
GeoVax issued 13.2 million units at $0.245 each with warrants for 26.5 million shares, using Roth Capital Partners as placement agent for the offering.
This funding supports GeoVax's work on vaccines for immunocompromised patients and cancer therapies, potentially improving global health outcomes.
GeoVax's public offering includes warrants exercisable for five years, offering investors a unique opportunity in biotechnology innovation.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs announced it has entered into agreements to raise approximately $3.2 million through a public offering of approximately 13.2 million units, each consisting of one share of common stock and warrants to purchase additional shares.
The company expects gross proceeds of approximately $3.2 million from the offering, with each unit priced at $0.245.
Each unit consists of one share of GeoVax common stock and warrants to purchase additional shares of common stock.
GeoVax will issue warrants to purchase up to approximately 26.5 million shares of common stock with an exercise price of $0.245 per share, exercisable immediately for five years following issuance.
The company intends to use the net proceeds for working capital and general corporate purposes.
The closing is expected to occur on or about December 22, 2025, subject to customary closing conditions.
Roth Capital Partners is acting as the exclusive placement agent for the offering.
GeoVax is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases.
The lead programs include GEO-CM04S1 (a next-generation COVID-19 vaccine in Phase 2 trials), Gedeptin® (an oncolytic solid tumor therapy), and a vaccine targeting Mpox and smallpox.
Electronic copies of the prospectus can be obtained on the SEC's website at http://www.sec.gov or by contacting Roth Capital Partners at (800) 678-9147 or 888 San Clemente Drive, Newport Beach CA 92660.
Curated from NewMediaWire
